Given that empagliflozin primarily affects renal glucose handling and has limited intestinal SGLT1 activity, its benefit in cases of impaired magnesium absorption, such as PPI-induced hypomagnesemia, may be modest. Here, SLC5A1 is linked to familial primary hypomagnesemia.